The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability.
The first study of SCT costs, however, was not published until 1989.
This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma.
Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues.
Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences.
Mots-clés Pascal : Lymphome, Leucémie, Autogreffe, Greffe, Homogreffe, Moelle osseuse, Cellule souche, Cellule hématopoïétique, Sang, Traitement, Analyse coût efficacité, Analyse coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Homme, Hémopathie maligne, Lymphoprolifératif syndrome
Mots-clés Pascal anglais : Lymphoma, Leukemia, Autograft, Graft, Homograft, Bone marrow, Stem cell, Hematopoietic cell, Blood, Treatment, Cost efficiency analysis, Cost analysis, Health economy, United States, North America, America, Human, Malignant hemopathy, Lymphoproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0197028
Code Inist : 002B27D02. Création : 11/09/1998.